Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Creative Medical Technology Holdings, Inc. (CELZ) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.89, with a market capitalisation of $5.79M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.62 to $6.25. This page covers its latest market performance, valuation, price trends and company information.
$5.79M | |
$0.92 | |
$51.45 | |
$0.62 | |
$0.89 | |
274.00 | |
9.69M | |
-- | |
$6.25 | |
$0.62 | |
-- | |
-- |
Creative Medical Technology Holdings, Inc. (CELZ) is trading at $0.89 in pre-market trading as of 2026-09-16 09:43:00, up 0.34% ($0.00) from the previous close of $0.89
Pre-market trading shows how investors are pricing CELZ before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Creative Medical Technology Holdings, Inc. (CELZ) moved from $1.11 to $0.89, representing a decline of 20.00% ($0.22).
The stock traded between $0.85 and $1.12 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 192.30 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.8%
CELZ is currently trading at $0.89, placing it 4.8% of the way from its 52-week low of $0.62 to its 52-week high of $6.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Creative Medical Technology Holdings, Inc. (CELZ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.